Skip to main content

Advertisement

Table 1 Clinical characteristics of healthy controls and asthmatic children before inhaled corticosteroid therapy showing mild, moderate and severe persistent asthma

From: Inhaled corticosteroid treatment for 6 months was not sufficient to normalize phagocytosis in asthmatic children

Parameters Normal control Mild persistent asthma Moderate persistent asthma Severe persistent asthma Test p
Number 21/78 24/58 (41.3%) 20/58 (34.5%) 14/58 (24.1%)  
Gender (boys/girls) 9/12 13/11 12/8 6/8 Chi-square p=0.64
Age (years) (mean±SD) 10.7±2.1 6.32±2.99 9.22±3.33 7.24±3.53 ANOVA* p<0.05
Total leukocytes 7390 9720 8120 8305 Kruskal-Wallis p=0.05
Neutrophils 3440 4150 3640 4260 Kruskal-Wallis p=0.66
Monocytes 568 568 536 643 Kruskal-Wallis p=0.57
Eosinophils 245 460 635 487 ANOVA p=0.003
BMI (Kg/m2) (mean±SD) 43.31±32.1 51.9±34.2 47.4±31.2 63.7±32.5 Kruskal-Wallis p=0.29
PEF (%) (mean±SD) 86.9±18.6 81.2±17.3 75.6±15.3 65.6±12.0 ANOVA** p<0.05
Treatment***      
ICS (%)   23/23 (100%) 10/20 (50%) 05/14 (35.7%)  
ICS + LABA (%)      
Budesonide + formoterol   0/23 (0%) 08/20 (40%) 04/14 (28.6%)  
Fluticasone propionate + salmeterol   0/23 (0%) 02/20 (10%) 05/14 (35.7%)  
  1. BMI Body Mass Index (percentile), PEF Peak Expiratory Flow, mPA mild persistent asthma, MPA moderate persistent asthma, SPA severe persistent asthma, mPA, MPA, SPA data before treatment. Beclomethasone dipropionate = 250 μg to 500 μg/day; Budesonide + formoterol 6/200 μg or 12/400 μg twice day; Fluticasone propionate + salmeterol = 25/125 μg to 50/250 μg twice day K-W= Kruskal-Wallis + Dunn’s method; * mPA and SPA < C; ** SPA < C; *** Treatment followed GINA.